An initiation of a Phase 1, first-in-human clinical trial of the preventative Ebola vaccine regimen consisting of MVA-BN® Filo and the AdVac® technology from Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, took place recently, said Bavarian Nordic A/S. The first volunteers have received their initial vaccine dose and recruitment in the trial is taking place, with enrollment slated for completion by the end of January.
Led by the Oxford Vaccines Group, part of the University of Oxford, Department of Pediatrics, the trial will assess the safety and tolerability of the heterologous prime-boost vaccination regimen in which patients first receive a dose to prime the immune system, and then a boost designed to increase the immune response over time. Seventy-two healthy adult volunteers are being divided into four groups receiving different regimens combining the two vaccine components.
